Background. Cellular therapies for immunomodulation in vascularized composite allotransplantation (VCA) have gained importance due to their potential for minimization of immunosuppression. Adipose-derived (AD) mesenchymal stem cells (MSCs) especially have shown encouraging potential. We investigated the influence of timing and frequency of AD-MSC treatment on immunologic and graft survival as well as graft vasculopathy outcomes after VCA. Methods. Lewis rats received full-mismatched Brown Norway rat hindlimb transplants. Recipient animals were assigned to groups receiving donor-derived AD-MSCs (10 6 cells/ animal) either on postoperative day (POD) 1, POD 4, or repeatedly on POD 4, 8, and 15, and compared to untreated controls. Results. Although AD-MSC administration on POD 1 or POD 4, 8, and 15 resulted in 50% long-term graft acceptance, recipients treated on POD 4, and controls rejected before POD 50. All treated animals revealed peripheral blood chimerism (4 weeks), most pronounced after repetitive cell administration (12.92% vs 5.03% [POD 1] vs 6.31% [POD 4]; P < 0.05; all P < 0.01 vs control 1.45%). Chimerism was associated with the generation of regulatory T cells (CD4
V ascularized composite allotransplantation (VCA) is the newest domain of solid organ transplants as defined by the Organ Procurement and Transplant Network Final Rule. 1 To date, 115 upper extremity, 35 face and other types of VCA such as uterus, abdominal wall, penis, trachea, bone, and joint have been performed worldwide to restore or reconstruct tissue defects that challenge conventional options. Technical feasibility, immunologic, functional, and graft survival outcomes have been promising but the need for lifelong multidrug immunosuppression remains a key obstacle to expansion of clinical VCA. [2] [3] [4] [5] [6] [7] Patient adherence to medications is key to minimizing the risks of acute or chronic rejection, both of which could lead to graft attrition or loss. 8, 9 However, immunosuppression can lead to life-threatening or life-shortening complications, such as infections, metabolic effects, end organ failure, [10] [11] [12] and malignancies. 13 These raise ethical questions of the time trade-off for young, otherwise healthy recipients receiving VCA which are mostly nonlife saving transplants unlike other solid organs.
Although true tolerance remains yet unattainable in clinical transplantation, immunomodulatory or tolerogenic cell therapies could be a near-term goal to help reduce dosing or frequency of immunosuppressive drugs, in turn expanding acceptance and clinical feasibility of VCA by improving the risk benefit equipoise of these procedures. [14] [15] [16] The immunomodulatory effects of mesenchymal stromal cells (MSCs) have been demonstrated in autoimmune disorders 17, 18 and experimental models of VCA. 15, [19] [20] [21] MSCs lack costimulatory molecules [22] [23] [24] and are thus immune-privileged in vivo. Clinical studies with MSCs confirm safety profiles of both autologous as well as allogeneic MSCs. 23, 25 Key immunomodulatory functionality of MSCs is purported to be due to their paracrine effects 23, [26] [27] [28] [29] or induction of regulatory T (T reg ) cells [30] [31] [32] as shown in animal models of VCA. 33, 34 Among MSCs, adipose-derived (AD) MSCs bear the inherent advantage of providing significantly higher cell yields compared to other sources and lower procurement-site morbidity. 35, 36 Additionally, our prior work and other emerging literature evidence lends credence to the higher immunomodulatory and immunosuppressive potential of AD-MSCs compared with their bone marrow (BM)-derived counterparts (BM-MSCs). [37] [38] [39] [40] Current standard of care induction and maintenance therapy in VCA, include antithymocyte globulin and tacrolimus (FK-506). Potential drug or antibody-induced adverse interactions can occur with MSCs, limiting cell viability or function as shown in studies on rodent and human MSCs. [41] [42] [43] [44] It is therefore important to account for the timing of cellular therapies when coupling them with conditioning and maintenance regimens. This is an area that merits further investigation.
In the present study, we investigated the immunomodulatory properties of AD-MSCs in a stringent rodent hindlimb allotransplantation model. In particular, we assessed the effect of timing and dosing frequency of AD-MSC treatment with relevance to the conditioning regimen, focusing on T reg induction and function, induction and persistence of donor chimerism, and allograft survival. We also assessed effects of AD-MSCs on chronic graft vasculopathy (GV) after VCA.
MATERIALS AND METHODS
All experiments were approved by the University of Pittsburgh Institutional Animal Care and Use Committee and were in compliance with Association for Assessment and Accreditation of Laboratory Animal Care guidelines.
Animals
Six-to eight-week-old male Lewis (LEW) (RT1 1 , recipient), Brown Norway (BN) (RT1 n , donor), and Wistar Furth (WF, RT1 u , third party donor) rats weighing 250 to 300 g. (Harlan, Indianapolis, IN) were housed in specific pathogen-free barrier caging at the University of Pittsburgh.
AD-MSC Isolation and Characterization
AD-MSC were isolated from adipose tissue excised from inguinal fat pads and bilateral epididymes of BN rats and enzymatically digested with collagenase type II (Worthington Biochemical Corp, Lakewood, NJ) and bovine serum albumin (Millipore, Billerica, MA) in Hanks balanced saline solution (Cellgro Mediatech Inc. Manassas, VA) for 60 minutes at 37°C with gentle shaking. The digested tissue was centrifuged at 1000 rpm for 10 minutes. The cellular pellet (stromal vascular fraction) was resuspended in erythrocyte lysis buffer and filtered through sterile gauze. Finally, the stromal vascular fraction was transferred to sterile culture flasks with Dulbecco modified Eagle medium (Cellgro Mediatech) plus supplemental Ham's F-12 medium (Gibco, Grand Island, NY). After an attachment period of 6 h, nonadherent cells were removed using a phosphate buffered saline (PBS) wash, leaving only the attached AD-MSCs. Cells were cultured in Dulbecco modified Eagle medium/F12 supplemented with 10% fetal bovine serum (ATLAS Biologicals, Fort Collins, CO), 0.1 μM dexamethasone (Sigma-Aldrich, St. Louis, MO), 1% penicillin-streptomycin (Gibco), and 1.25 mg/L amphotericin B (Gibco) and expanded in vitro until passage 3.
For surface marker analysis, cells were detached with 0.25% trypsin solution (Cellgro Mediatech Inc.), washed, and suspended with PBS. Cells were stained with anti-rat CD29, CD73, CD90, and CD45 antibodies. The cells were then analyzed using an LSRII flow cytometer (fluorescenceactivated cell sorting) using FlowJo software (TreeStar Inc., Ashland, OR). AD-MSCs were positive for CD29, CD73, and CD90 markers and negative for CD45 marker.
Antilymphocyte Serum Effects
Rabbit-anti-rat-lymphocyte polyclonal serum was purchased from Cedarlane (Burlington, Ontario). Naïve LEW rats were treated with antilymphocyte serum (ALS) (300 μL) intraperitoneally to assess white blood cell (leucocyte) depletion in vivo. Blood was collected on day 0 (baseline, before injection), 1, 3, 6, and 10 after single ALS administration for monitoring leucocyte counts in nontransplanted naive Lewis rats.
Surgical Model
LEW rats received orthotopic hindlimb transplants from BN donor rats as described in our prior studies. 45 An isoflurane vaporizer (VetEquip, Inc., Pleasanton, CA) provided gas concentrations at 2%. Both legs of BN donors were shaved and retrieved through a circumferential skin incision, ligation of epigastric vessels, dissection of femoral vessels, and transection at the level of the inguinal ligament. The leg was then amputated at mid-femoral level. The femoral artery of the allograft was flushed with 5 mL of cold heparinized Ringer lactate solution and then stored at 4°C. The amputation of the LEW recipient leg was performed in a similar fashion, with transection of the vessels at a more distal level than the donor. Osteosynthesis was performed using an 18-gauge needle as an intramedullary rod. The sciatic nerve was adapted using 9-0 nylon sutures (Microsurgery Instruments, Inc., Bellaire, TX), and the muscles were sutured with interrupted 4-0 vicryl sutures (Ethicon Inc., Somerville, NJ). Microsurgical anastomosis of the femoral artery was performed with interrupted 11-0 nylon sutures, whereas a polyamide tube (RiverTech Medical, Chattanooga, TN) was used as cuff for the femoral vein as previously reported. 46 
Experimental Protocol
All recipients were treated with ALS (300 μL) 4 days before and 1 day after surgery. Immunosuppression with FK-506 (0.5 mg/kg) was administered intraperitoneally to all animals on a daily basis from the day of surgery (day 0) to postoperative day (POD) 21.
Animals were assigned randomly to the groups. The experimental groups received 1 Â 10 6 AD-MSCs suspended in 1 mL of PBS administered either on POD 1 (n = 8), POD 4 (n = 7), or repeatedly on POD 4, 8, and 15 (n = 8). For this purpose, the animals were anesthetized as described above and the cell aliquots were slowly injected through the penile vein using a 30-gauge needle. Control animals received no cellular treatment (n = 5). After 4 weeks, blood was collected for peripheral chimerism and T reg level assessment. Animals were observed on a daily basis for signs of rejection, which was assessed according to clinical VCA rejection grading. 47 Rejection grade III or long term survival > 120 days were defined as endpoints. Once an endpoint was reached, animals were sacrificed for tissue sampling. Lymphatic organs and peripheral blood were collected from long-term survivors at sacrifice for further in vitro immunological assessment. In 2 long-term survivors after repetitive AD-MSC treatment donor specific graft tolerance was challenged with a secondary BN skin graft.
Chimerism and T reg Analysis
To detect chimerism in the peripheral blood, mouse antirat class I RT1Ac antibodies (AbD Serotec) were used for labeling donor cells (RT1 n , BN rats), and mouse anti-rat CD45Ra, CD11b/c, CD4, and CD8 antibodies (eBioscience) were used as markers of cell lineages. Cells were then analyzed using an LSRII flow cytometer and data was analyzed using FlowJo software.
Peripheral blood was routinely collected for analysis of peripheral chimerism and T reg levels on POD 28. For T reg analysis, red blood cells were lysed with erythrocyte lysing buffer (eBioscience, San Diego, CA) stained with various cell surface markers (fluorochrome-conjugated mouse anti-rat CD3, CD4, CD8, CD25, CD11b/c, CD45RA antibodies) or intracellular markers (fluorochrome-conjugated mouse anti-rat Foxp3 antibody), and then analyzed using an LSRII flow cytometer. Data were analyzed using FlowJo software.
Mixed Lymphocyte Reaction Assays
For T cell proliferation assays, peripheral blood mononuclear cells (PBMCs) (2 Â 10 5 cells/well) or CD4 + CD25
− T cells (T effs , 2 Â 10 5 cells/well) were isolated from the blood or spleens and lymph nodes of LEW naïve rats and long-term surviving hindlimb allograft recipient rats (AAA3 and AAA5, repetitive AD-MSC treatment) and cocultured in triplicates with irradiated (3000 rads) PBMCs or splenocytes (5 Â 10 4 cells/well) in 96-well culture plates for 6 days. Stimulator PBMCs and splenocytes were isolated from the blood or spleens, respectively, of donor BN rats as well as thirdparty WF rats. 
Histopathology
Femoral arteries were harvested from the transplanted grafts at the endpoint. Samples were collected from longterm-surviving allografts in AD-MSC-treated animals on day 120 and rejecting controls (grades I and III). In addition, naive femoral artery samples were collected from BN rats. Samples were immediately fixed in Bouin's fixative (Ricca Chemical Company, Arlington, TX) for 24 hours. After fixation, samples were washed in PBS with lithium carbonate and incubated overnight in 5% gelatin/sucrose. Samples were then cryopreserved in fresh gelatin/sucrose solution and 10-μm-thick sections were cut until all vessel wall layers were clearly exposed. Sections were washed in PBS at 37°C and incubated in 0.1 M acetic acid solution (37°C) to eliminate gelatin residues and washed again in PBS. Sections were stained for elastin. Samples were imaged with an Olympus Provis 1 microscope (Olympus America, Center Valley, PA) at 20Â magnification. Tunica, intima, and media thickness in graft femoral arteries were measured using ImageJ (National Institute of Health, Bethesda, MD) as described previously. 45 Intimal thickness was defined as (intima/[intima + media]) Â 100; intima/media ratio as (intima/media) Â 100.
Statistical Analysis
InStat and Prism 5.0 software (GraphPad Software, La Jolla, CA) was used for statistical analysis. The data is presented as means ± SD unless otherwise indicated. Differences between the groups were assessed by one-way ANOVA and Bonferroni multiple comparison posttest. Data showed normal distribution. Graft survival was compared between the different groups using Kaplan-Meier analysis. A value of P less than 0.05 was chosen to represent statistical significance.
RESULTS

ALS Conditioning Results in Temporary Leucocyte Depletion In Vivo
Leucocyte counts significantly decreased in vivo, declining from 12.95 ± 2.06 to 2.78 ± 1.65 Â 10 3 /mL within 24 hours after ALS administration (Figure 1 ). Levels remained significantly lower compared to baseline (P < 0.01 baseline vs days 1, 3, and 6) for 6 days and showed significant recovery only after 10 days (8.53 ± 2.60 Â 10 3 /mL, P < 0.05 vs day 1).
Multiple AD-MSC Administration Improves Allograft Survival Compared With Single Treatment
All transplanted limbs were rejected in control animals within 7 weeks (Figure 2 ). All animals receiving singleadministration of AD-MSCs on POD 4 rejected within 8 weeks. In the group receiving single-administration of AD-MSCs on POD 1, 60% of recipients demonstrated graft survival over 12 weeks and 50% of the remaining grafts survived over 15 weeks. Repeated AD-MSC administration on FIGURE 1. The effect of ALS on white blood cell (leucocyte) count. Leucocyte levels were analyzed in naive rats over 10 days after ALS administration. WBCs decreased significantly within 24 hours (P < 0.01) and only recovered slowly until reaching significantly increased levels on day 10 (P < 0.05 vs day 1). WBC, white blood cells. POD 4, 8, and 15 resulted in graft survival over 15 weeks in 50% recipients. Two animals in this group were investigated more in-depth (AAA3 and AAA5) for in vitro assessment of immune tolerance. Two other long-term survivors (AAA7 and AAA8) received secondary donor skin grafts to challenge donor specific graft tolerance. Recipient AAA7 (Figure 3 ) accepted the donor skin graft while recipient AAA8 rejected it. Donor skin grafting in AAA8 also triggered hindlimb allograft rejection and was eventually euthanized on day 150 after transplantation.
Repetitive AD-MSC Administration Induces Sustained and Significant T reg Upregulation Compared to Single Treatment
Peripheral multilineage chimerism was detected in the blood of all animals treated with AD-MSCs after 4 weeks (Figure 4) . Animals receiving 1 dose of AD-MSCs on day 1 or day 4 showed significantly higher levels of T reg compared with controls (P < 0.01). However, upregulation of T reg was most pronounced after repetitive AD-MSC treatment (12.9 ± 7.5 %, P < 0.05 vs day 1 and day 4, P < 0.01 vs controls; Figure 5 ). Repetitive AD-MSC treatment significantly increased T reg levels to 17.8 ± 9.8% compared with controls (P < 0.01) and single-shot treatment groups (P < 0.01 vs day 1 and P < 0.05 vs day 4). Although peripheral blood chimerism did not persist in long-term survivors at 17 weeks ( Figure 6A ), T reg levels were significantly higher after repetitive treatment in AAA3 (6.4%) and AAA5 (4.5%) rats compared with naive controls (2.2%; Figure 6B ).
Repetitive AD-MSC Results in Suppressed T Cell Function In Vitro on Mixed Lymphocyte Reactivity Assay
After stimulation by either irradiated donor (BN) or third party (WF) PBMCs, PBMCs from AAA3 and AAA5 rats exhibited lower proliferative responses compared with naive animals (naive 3685 ± 387 cpm; AAA3 2500 ± 763 and AAA5 1340 ± 350 for BN-PBMCs; P < 0.001 vs naive; naive 3974 ± 528, AAA3 2023 ± 642 and AAA5 1946 ± 28 cpm for WF-PBMC; P < 0.001 vs naive; Figure 7 ). Flow-sorted T effs from AAA3 and AAA5 rats, which did not contain T reg , exhibited a lower proliferation response (39 550 ± 636 and 23 540 ± 2938 cpm, respectively) than those from naive animals (96 380 ± 13 070; P < 0.001) after being stimulated by donor (BN) antigen-presenting cells (APCs). Similar results were found after stimulation with third party (WF) APCs (naive 101 448 ± 11 233 cpm; AAA3 40 648 ± 922 cpm and AAA5 37 263 ± 5 874 cpm; P < 0.001 vs naive) (Figure 8 ). T reg from AAA3 rats, but not AAA5 rats, markedly inhibited naïve T eff proliferation (40 390 ± 1016 [AAA3] vs 77350 ± 1014 [naïve] cpm; P < 0.001) at a suppressor/responder ratio of 1:4 when stimulated by APC from Ag-specific donor (BN) rats, whereas no significant difference among groups was found using a suppressor/responder ratio of 1:1. Furthermore, no significant difference was found in the suppressive function of T reg between naïve, AAA3, and AAA5 rats when T effs were stimulated by APCs from non-Ag-specific third party (WF) rats (Figure 9 ; 42000 ± 5791 vs 37 440 ± 3 528 vs 31 890 ± 1273 cpm, respectively; P < 0.05).
AD-MSC Treatment Suppresses Development of Chronic Graft Vasculopathy in Long-Term Survivors
Compared with naive animals (18.48 ± 7.77%), the intimal thickness of rejected allografts was significantly increased (42.87 ± 6.9% [grade I] and 48.76 ± 10.6% [grade III]; both P < 0.001). Rejected grafts showed a significantly higher intimal thickness than AD-MSC-treated long-term survivors (17.06 ± 9.2%, P < 0.001 vs grades I and III). Similar results were found for intima/media ratio; although rejecting animals revealed elevated values (77. 22 animals (23.7 ± 12.44%; P < 0.001 vs grade I and III rejection; Figure 10 ).
DISCUSSION
Immunomodulatory strategies involving repetitive MSC administration have shown promise in small and large animal models. 48, 49 Graft survival seems to correlate with T reg levels in experimental VCA. 34, 50 In our study, both the early single treatment and the repetitive AD-MSC administration strategies were able to significantly prolong allograft survival. However, analysis of T cell function and especially T reg (CD4 + CD25 hi FoxP3 + ) modulation suggests a superior tolerogenic potential of the multidosing regimen. We found sustained higher levels of T reg compared with controls, leading to long-term VCA acceptance.
The administered AD-MSCs were characterized by typical mesenchymal surface marker phenotypes (CD29 hi CD73 hi CD90 hi CD45 − ) as described previously. 40, 51 As demonstrated earlier in in vitro studies by our group, ALS exposure leads to decreased viability, differentiation, and proliferation parameters of AD-MSCs at a clinically relevant dose range. Similar effects were seen with FK-506, rapamycin, and mycophenolic acid on MSCs. 43, 52 Other studies as by Buron et al 44 have shown that immunosuppressive drugs can increase or antagonize the beneficial effects of MSC. For example, Cyclosporine (CsA) has shown lower toxicity compared to FK-506 in VCA in rodent and swine MSCbased protocols, as demonstrated by other groups. 33, 41, 48 Therefore, selection of the appropriate conditioning regimen is of utmost importance when coupled with cell-based therapies to avoid negative collateral toxicity. Conditioning with irradiation or selective antibodies may serve as alternative conditioning regimens. 41, 53 Timing of cell therapy with respect to induction treatments is also crucial and needs to be adjusted to adequately prepare the recipient for transplantation, while avoiding drug toxicity to cells used concomitantly for immunomodulation.
Delayed administration of AD-MSCs on day 4 was associated with worse outcomes compared with day 1 injection. The reasons for this remain to be conclusively investigated in future studies, but we hypothesize as follows: The earliest reports on the in vivo effects of ALS on lymphocytes and hematopoietic stem cells confirm that ALS has cytotoxic and cytolytic effects. 54, 55 The recipient alloresponse to the donor antigens and allosensitization occurs during the first few days after VCA. Cell surface coating and splenic removal mostly mediate the acute cytotoxic effects of ALS on lymphocytes. This may occur with MSC as well. However, the cytolytic effects of ALS are mediated by complement mediated cell lysis. Complement development in the recipient against donor antigens may take 24 to 72 hours to occur. 56, 57 Thus, MSCs administered on day 4 may be prone to both cytotoxic effects as well as complement-mediated lysis while those on day 1 may be relatively spared from the effects of complement. Cytotoxic and/or cytolytic effects of ALS may have variable deleterious influence on functional effects of MSC (homing, paracrine, or proliferation). 58, 59 Our findings indicate that in vitro effects of these drugs may not translate uniformly and equivocally into the in vivo setting. After ALS injection, lymphocyte counts were markedly depleted and slowly recovered, reaching baseline levels after almost 2 weeks. The repetitive AD-MSC administration protocol was aimed at establishing a sustained immunomodulatory effect during a permissive time window early after 
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+ T reg were elevated in peripheral blood from AAA3 (6.38%) and AAA5 (4.84%) rats compared with a naïve control (2.18%).
FIGURE 7.
PBMCs from AAA3 and AAA5 rats exhibited a lower proliferative response than PBMCs from naïve animals after being stimulated by irradiated allogenic PBMCs, either from same donor (BN) or from a third party (WF), suggesting an attenuated alloresponse in these 2 long-term tolerant animals. FIGURE 8. T effs from AAA3 and AAA5 rats exhibited a lower proliferative response than those from naïve animals after being stimulated by either same donor (BN) or third party (WF) antigen-presenting cells. This suggests that T effs from long-term graft survival animals showed a nonspecific and donor-independent reduced immune response to alloantigens even in the absence of T reg suppression.
transplantation. Upregulation of T reg may be a temporary finding as found earlier in our own series. 40 However, we speculate that additional AD-MSC administration at later timepoints may have potential to maintain higher T reg levels and further improve outcomes.
Given the known cytotoxic ALS effects on AD-MSCs in vitro, repetitive dosing seems to be a successful strategy to overcome any potential in vivo collateral adverse effects on cell viability. Besides these effects, a "first-pass" effect of filtering organs might sequester MSCs after systemic injection and require higher cell doses and multiple administrations. 60, 61 In previous studies, we found that at least some of intravenously administered cells had homed to sites of tissue injury. 58 It is not yet clear whether MSCs need to home to allografts or to recipient-donor interfaces for beneficial effects for tolerance induction. Furthermore, we found AD-MSCs to be significantly smaller than BM-MSCs, 52 which might decrease organ entrapment and favor their homing to target tissues, which agrees with similar findings from Rider et al. 62 Even though prolongation of elevated T reg levels was observed, stable chimerism was not achieved in long-term tolerant animals. Some authors argue that stable mixed chimerism is a prerequisite for long-term donor-specific tolerance. 63 Kuo and colleagues 33 achieved long-term peripheral blood chimerism (>150 days) after serial AD-MSC injections with increased T reg levels in peripheral blood and skin after 4 weeks, which eventually decreased to naïve levels later in a similar rodent VCA model as in this study. In contrast, in a more recent report, Cheng et al 50 used syngeneic AD-MSCs and found a delayed T reg increase starting later than 4 weeks postoperatively but remaining at high levels in the follow-up of long-term tolerant recipients. Their regimen used a single treatment of syngeneic AD-MSC injection, which achieved a slightly higher graft acceptance (66%) as compared with our study, whereas Kuo and his group reached long-term graft survival in almost 90% of the animals following multiple injections. It remains to be investigated whether long-term tolerance can be achieved with sole AD-MSC treatment or if combination therapies with agents, such as hematopoietic cells or bone marrow, would be more effective either alone or in combination with AD-MSC. Preliminary data in clinical hematopoietic stem cell transplantation have provided some early clues that MSCs may be efficacious in facilitating engraftment or reestablishing functional bone marrow without graftversus-host disease. 64 To our knowledge, this is the first study to assess in vitro T cell function in long-term VCA-tolerant animals after repetitive administration of AD-MSCs and correlation with T reg activity in vivo. In general, we found no significant differences in T eff suppression by T reg from long-term tolerant animals when stimulated by donor-specific APCs compared to naïve T reg , besides at a 4:1 effector/suppressor rate, where AAA3 rats showed a significantly higher suppressive function on T effs . In all animals, we could demonstrate immunocompetent T reg as evidenced by clear modulation of the T eff response. There was no significant difference between T reg from naive animals and those from long-term animals when stimulated by third party (WF) APCs, which suggests donornon-specific T reg function. T effs from AAA3 and AAA5 animals showed a weaker immune response when stimulated ex vivo compared to naive T effs , suggesting a different immunologic behavior after AD-MSC administration. This was confirmed by experiments on the immunoresponse of recipient PBMCs toward donor and third-party APCs. Again, PBMCs from long-term survivors responded lesser than PBMCs from naive animals. A previous report showed that MSCs were able to alter T cell function from a proinflammatory to an anti-inflammatory phenotype in vitro. 65 Another in vitro study reports the ability of human AD-MSCs to inhibit T cell responses and upregulate T reg . [30] [31] [32] Our results concur with prior studies.
Secondary skin grafting in long-term tolerant animals resulted in abrogation of the tolerance state indicating that true or stable tolerance was not achieved. Although the mechanisms underlying this phenomenon are outside the scope of this study, it may be reasonable to conclude that AD-MSC-mediated immunomodulation resulted in prope-tolerance or a state of graft acceptance without immunosuppression.
Chronic GV is the sine-qua-non of chronic rejection across all solid organs including VCA. We identified significant differences in GV as estimated by intima-media thickness evaluation of the large femoral arteries between rejecting animals and AD-MSC-treated long-term survivors, with the latter revealing normal intima-media thickness, comparable to values of naïve arteries. Naive animals were compared to long-term surviving animals that had received AD-MSC treatment (day 1 and repetitive group). In those animals that did not undergo rejection, AD-MSC treatment was associated with absence of intimal hyperplasia. However, rejecting animals at different grades (grades I and III) from different groups uniformly showed pathological vascular changes. In addition to the split-rejection phenomenon observed solely in the skin component, we were able to demonstrate GV that occurred in animals with both lower grade (Banff I) as well as in animals with advanced rejection (Banff III). This may support the hypothesis that the skin may not be a true sentinel of chronic graft rejection, which is characterized by GV in the subdermal vasculature with minimal skin changes.
As shown by our group, MSCs are capable of inducing vascular changes, such as neoarteriogenesis and remodeling. 59 Other groups have reported that MSC treatment ameliorates inflammatory arterial intima thickening, such as during arteriosclerotic development 66 or after VCA. 67 The intimal thickness ratio was calculated based on measurements assessed by ultrasound investigation of the major graft arteries by Kückelhaus et al 67 in a study that correlated GV with clinical outcomes in VCA grafts. Our study is the first, albeit pilot report on GV in large graft arteries (femoral vessels) and AD-MSC-mediated inhibition of GV in VCA. We intend to explore this finding conclusively in a larger study to identify AD-MSC-based strategies for inhibition or reversal of intimal hyperplasia in VCA.
Taken together, our in vitro results point to superior potential of repetitive AD-MSC administration compared to in vivo outcomes in VCA. The differential improvement or effect on graft survival across different time points as studied supports the potential for future studies into optimization of the AD-MSC therapy dosing and frequency, combination with other cell therapies (such as HSC or BM-MSC or dendritic cells) as well as selection of appropriate conditioning or maintenance drug regimens. Repetitive AD-MSC treatment, in conjunction with a selected conditioning regimen and short-term immunosuppression, may be a promising strategy to achieve long-term survival of VCA by its effects on T reg upregulation, suppression of progression of GV and promoting an immunomodulatory graft milieu.
